Mr. Schwab is a Founder and Managing Partner of 5AM Ventures. Prior to founding 5AM in 2002, Mr. Schwab was a Principal at Bay City Capital where he was involved with such companies as Cubist, PTC Therapeutics, Symyx and Syrrx. Previously Mr. Schwab was Vice President of Business Development at Digital Gene Technologies and a Vice President in the life science investment banking group of Montgomery Securities. In addition to Bird Rock Bio, at 5AM, he has led the firm’s investments in and served on the Boards of Directors of Biodesy, Cleave, DVS (acquired by Fluidigm), Flexion (NASDAQ: FLXN), Ikaria (acquired by Mallinckrodt and spun-out Bellerophon (NASDAQ: BLPH)), Ilypsa (acquired by Amgen), Miikana (acquired by EntreMed), Panomics (acquired by Affymetrix), Pear Therapeutics, Precision NanoSystems, Synosia (acquired by Biotie) and Viveve (OTC: VIVMF). Mr. Schwab also serves on the Board of Trustees of the California Academy of Sciences. Mr. Schwab earned a BS with Honors in Genetics & Ethics from Davidson College and was a member of Davidson’s 1992 Final Four soccer team.
Bradley J. Bolzon, PhD
Dr. Bolzon is a Managing Director at Versant Ventures. Prior to joining Versant, he served as Executive Vice President, Global Head of Business Development, Licensing & Alliances with F. Hoffmann-La Roche. Under his leadership, Roche established alliances with over 75 biotech companies worldwide and significantly strengthened its product pipeline. Previously, he held executive roles at Eli Lilly in drug discovery, clinical research, regulatory affairs, and business development. In addition to Bird Rock Bio, Dr. Bolzon currently serves as a Board Member for Blueline Bioscience, CRISPR Therapeutics, Highline Therapeutics, Inception Sciences, Kyras Therapeutics and Northern Biologics. He earned a PhD and MS at the University of Toronto.
Simeon J. George, MD
Dr. George is a Partner at SR One where he leads the firm’s investment activities on the West Coast. Prior to joining SR One, he was a consultant at Bain & Company and an investment banker at Goldman Sachs and Merrill Lynch. In addition to Bird Rock Bio, he currently serves as a Board Member for eFFECTOR Therapeutics, Genocea Biosciences, HTG Molecular, Principia Biopharma and Progyny, Inc. Dr. George holds a medical degree and an MBA from the University of Pennsylvania and a BA in Neuroscience from the Johns Hopkins University, where he graduated Phi Betta Kappa.
Paul A. Grayson
Chief Executive Officer
Mr. Grayson previously served as CEO of Fate Therapeutics (NASDAQ: FATE). Before this, he was managing director of Sanderling Ventures. Prior to Sanderling, Mr. Grayson served as the founding Chairman and CEO of Senomyx Inc. (NASDAQ: SNMX). He earned an MBA from the University of California, Irvine, and a BA in Computer Science and Biochemistry from the University of California, Los Angeles.
Allan Marchington, PhD
Dr. Marchington was a founder and Partner at Apposite Capital a London based healthcare investor. He was formerly at Abingworth Management and prior to this was a member of Millennium Pharmaceuticals management team as a Senior Vice President with responsibility for all technology investments. Dr. Marchington also served as Chairman of Millennium Pharmaceuticals in Europe. Allan joined Millennium following their acquisition in July 2000 of Cambridge Discovery Chemistry, where he was CEO and founder. He began his career as a medicinal chemist at Pfizer Central Research. In addition to Bird Rock Bio, Dr. Marchington currently serves as a Board Member for Calchan. He earned a PhD in Chemistry from the University of Liverpool.
Simon Nebel, PhD
Dr. Nebel is a Managing Partner at Aravis, where he has participated in the financing of a number of life science companies and the M&A transactions for a number of Aravis portfolio companies. He is the co-founder of Aravis Energy I LP, the first Swiss Limited Partnership focused on renewable energy. Before joining Aravis, he was a group strategist at UBS. In addition to Bird Rock Bio, Dr. Nebel currently serves as a Board Member for SynAffix (NL), MarinoMed (AT), and Leading Swiss Renewable Energy AG. He earned a PhD in Biophysics from the Biocentre of the University of Basel and an MBA with distinction from the London Business School.
Peppi Prasit, PhD
Dr. Peppi Prasit is the founder and CEO of Inception Sciences. Previously, he was the co-founder and chief scientific officer of Amira Pharmaceuticals, which was acquired by Bristol Myers Squibb. Dr. Prasit has more than 20 years of experience in pharmaceutical research and management serving in various positions with Merck Frosst Canada and more recently at Merck San Diego. During this time, he played a pivotal role in the discovery of multiple marketed drugs. Dr. Prasit received his BS from UCL, London University, and his PhD from Victoria University of Wellington in New Zealand and served as a postdoctoral fellow at Princeton University.
Raymond Stevens, PhD
Dr. Stevens is the Provost Professor of Molecular Biology and Chemistry at the University of Southern California in Los Angeles, California and Distinguished Professor at the iHuman Institute, ShanghaiTech University in Shanghai, China. He obtained his Ph.D. in chemistry in 1988 and conducted his post-doctoral research in structural biology in the Chemistry Department at Harvard University. Dr. Stevens has helped to pioneer the areas of high throughput structural biology and GPCR structure-function, publishing more than 350 peer reviewed publications in the past 20 years. His research is focused in the area of structural biology and structure based drug discovery including involvement in the development of TamifluTM for influenza virus, KuvanTM for mild phenylketonuria, Peg-palTM for classical phenylketonuria, and alogliptin for type II diabetes. He has also founded four biotech companies – Syrrx, MemRx, Receptos, and Bird Rock Bio, two international research institutes, iHuman Institute in Shanghai, China and the Bridge Institute in Los Angeles, CA and 4 NIH Centers.